Home/ Stocks/ ABUS

Arbutus Biopharma Corporation Common Stock

ABUS XNAS

$4.33 -0.15 (-3.27%) ▼ 15-min delayed

Open

$4.51

High

$4.52

Low

$4.31

Volume

1.43M

Market Cap

$892.87M

About Arbutus Biopharma Corporation Common Stock

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 19 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$179.13M	$169.69M	$0.88
FY 2025	$14.08M	$-33,501,000	$-0.17
Q3 2025	$529.0K	$-7,742,000	$-0.04
Q2 2025	$10.74M	$2.52M	$0.01

Related Market News

No specific coverage for ABUS yet. Check out our latest market news or earnings calendar.

Get ABUS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Arbutus Biopharma Corporation Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.